|
US6582921B2
(en)
|
1996-07-29 |
2003-06-24 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses thereof
|
|
US7098320B1
(en)
|
1996-07-29 |
2006-08-29 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
US6506564B1
(en)
|
1996-07-29 |
2003-01-14 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
US7169556B2
(en)
|
1996-07-29 |
2007-01-30 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
AU4043497A
(en)
|
1996-07-29 |
1998-02-20 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
US6984491B2
(en)
|
1996-07-29 |
2006-01-10 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
US6750016B2
(en)
|
1996-07-29 |
2004-06-15 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
US6974669B2
(en)
|
2000-03-28 |
2005-12-13 |
Nanosphere, Inc. |
Bio-barcodes based on oligonucleotide-modified nanoparticles
|
|
US7323179B2
(en)
*
|
1997-12-19 |
2008-01-29 |
Naomi Balaban |
Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
|
|
AU768535B2
(en)
|
1998-11-30 |
2003-12-18 |
Nanosphere, Inc. |
Nanoparticles with polymer shells
|
|
EP1294930B1
(en)
|
2000-01-13 |
2011-03-30 |
Nanosphere, Inc. |
Nanoparticles having oligonucleotides attached thereto and uses therefor
|
|
AU2001276870B2
(en)
|
2000-07-11 |
2006-07-20 |
Northwestern University |
Method of detection by enhancement of silver staining
|
|
US7238472B2
(en)
|
2001-05-25 |
2007-07-03 |
Nanosphere, Inc. |
Non-alloying core shell nanoparticles
|
|
US7147687B2
(en)
|
2001-05-25 |
2006-12-12 |
Nanosphere, Inc. |
Non-alloying core shell nanoparticles
|
|
UA78726C2
(en)
*
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
|
US7186814B2
(en)
|
2001-11-09 |
2007-03-06 |
Nanosphere, Inc. |
Bioconjugate-nanoparticle probes
|
|
KR100479735B1
(ko)
*
|
2002-05-25 |
2005-03-30 |
이현철 |
대식세포특이 나노입자-면역조절제-면역원 복합체를이용한 치아우식증을 예방하는 비경구용 백신
|
|
EP1540006B1
(en)
|
2002-07-02 |
2009-01-07 |
Nanosphere, Inc. |
Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
|
|
KR20050086819A
(ko)
|
2002-11-25 |
2005-08-30 |
시클론 파마수티컬 인코포레이티드 |
알파 티모신을 사용한 방사능 손상에 대한 보호방법
|
|
ES2427092T3
(es)
|
2003-04-10 |
2013-10-28 |
Evonik Corporation |
Un método para la producción de micropartículas a base de emulsión
|
|
US20070207211A1
(en)
*
|
2003-04-10 |
2007-09-06 |
Pr Pharmaceuticals, Inc. |
Emulsion-based microparticles and methods for the production thereof
|
|
BRPI0409322B8
(pt)
*
|
2003-04-11 |
2021-05-25 |
Antriabio Inc |
método para preparar um conjugado de insulina-polímero
|
|
US8815284B2
(en)
|
2003-06-26 |
2014-08-26 |
Psivida Us, Inc. |
Bioerodible sustained release drug delivery systems
|
|
DK1635875T3
(da)
*
|
2003-06-26 |
2009-01-12 |
Psivida Inc |
In-situ-geldannende lægemiddeladministrationssystem
|
|
WO2005009356A2
(en)
*
|
2003-07-15 |
2005-02-03 |
Pr Pharmaceuticals, Inc. |
Method for the preparation of controlled release formulations
|
|
EP2444069B1
(en)
|
2003-07-23 |
2019-06-05 |
Evonik Corporation |
Controlled release compositions
|
|
US7906148B2
(en)
|
2003-07-31 |
2011-03-15 |
Boston Scientific Scimed, Inc. |
Latex medical articles for release of antimicrobial agents
|
|
AU2003282780A1
(en)
|
2003-08-08 |
2005-03-07 |
Abgenix, Inc. |
Antibodies directed to parathyroid hormone (pth) and uses thereof
|
|
US7318925B2
(en)
*
|
2003-08-08 |
2008-01-15 |
Amgen Fremont, Inc. |
Methods of use for antibodies against parathyroid hormone
|
|
US20070026005A1
(en)
*
|
2003-09-09 |
2007-02-01 |
Sung Young C |
Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
|
|
ES2246694B1
(es)
*
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
WO2005107714A2
(en)
*
|
2004-05-05 |
2005-11-17 |
Alkermes Controlled Therapeutics, Inc. |
Method of forming microparticles that include a bisphosphonate and a polymer
|
|
US9561309B2
(en)
*
|
2004-05-27 |
2017-02-07 |
Advanced Cardiovascular Systems, Inc. |
Antifouling heparin coatings
|
|
EP1768700B1
(en)
*
|
2004-07-16 |
2010-12-15 |
Nektar Therapeutics |
Conjugates comprising gm-csf and a polymer
|
|
US7875700B2
(en)
|
2004-07-19 |
2011-01-25 |
Biocon Limited |
Cation complexes of insulin compound conjugates, formulation and uses thereof
|
|
US8420602B2
(en)
*
|
2004-09-14 |
2013-04-16 |
Landon C. G. Miller |
Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
|
|
CA2590239A1
(en)
*
|
2004-12-23 |
2006-07-06 |
Durect Corporation |
Controlled release compositions
|
|
US7794742B2
(en)
*
|
2005-02-08 |
2010-09-14 |
University Of Washington |
Devices for promoting epithelial cell differentiation and keratinization
|
|
US7824691B2
(en)
*
|
2005-04-04 |
2010-11-02 |
Centegen, Inc. |
Use of RIP in treating staphylococcus aureus infections
|
|
WO2006122127A1
(en)
*
|
2005-05-10 |
2006-11-16 |
Naomi Balaban |
Compositions for administering rnaiii-inhibiting peptides
|
|
US20060263328A1
(en)
*
|
2005-05-19 |
2006-11-23 |
Sang Van |
Hydrophilic polymers with pendant functional groups and method thereof
|
|
US20070031512A1
(en)
*
|
2005-08-03 |
2007-02-08 |
Amcol International Corporation |
Virus-interacting layered phyllosilicates and methods of inactivating viruses
|
|
US20100272769A1
(en)
*
|
2005-08-03 |
2010-10-28 |
Amcol International |
Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
|
|
US20080184618A1
(en)
*
|
2005-08-03 |
2008-08-07 |
Amcol International |
Virus-Interacting Layered Phyllosilicates and Methods of Use
|
|
CN1939316B
(zh)
*
|
2005-09-28 |
2012-01-25 |
中国人民解放军军事医学科学院毒物药物研究所 |
含阿霉素的微球及其制备方法
|
|
US20070141160A1
(en)
*
|
2005-12-15 |
2007-06-21 |
Brown Laura J |
Method of treatment for osteoarthritis by local intra-articular injection of microparticles
|
|
CU23388B6
(es)
*
|
2006-01-31 |
2009-07-16 |
Ct Ingenieria Genetica Biotech |
Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
|
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
WO2007092252A2
(en)
*
|
2006-02-03 |
2007-08-16 |
Modigene Inc |
Long-acting polypeptides and methods of producing same
|
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
|
EA200870575A1
(ru)
*
|
2006-05-26 |
2009-08-28 |
Амилин Фармасьютикалз, Инк. |
Композиции и способы лечения застойной сердечной недостаточности
|
|
US20090053210A1
(en)
*
|
2006-09-01 |
2009-02-26 |
Roland Buelow |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
|
US20090252703A1
(en)
*
|
2006-10-19 |
2009-10-08 |
Gegg Jr Colin V |
Use of alcohol co-solvents to improve pegylation reaction yields
|
|
US20080287341A1
(en)
*
|
2007-05-18 |
2008-11-20 |
Danyang Chen |
Treatment of vascular abnormalities using nanoparticles
|
|
EP2431043A1
(en)
|
2007-05-23 |
2012-03-21 |
Amcol International Corporation |
Cholesterol-interacting layered phyllosilicates for suppressing gastrointestinal cholesterol absorption
|
|
MX2010003979A
(es)
*
|
2007-10-16 |
2010-06-02 |
Biocon Ltd |
Composicion farmaceutica oralmente administrable y proceso para su preparacion.
|
|
WO2009052301A1
(en)
*
|
2007-10-16 |
2009-04-23 |
Regado Biosciences, Inc. |
Steady-state subcutaneous administration of aptamers
|
|
WO2009061428A1
(en)
|
2007-11-06 |
2009-05-14 |
Kline Ellis L |
Compositions and methods for treating parkinson's disease and related disorders
|
|
AR069674A1
(es)
*
|
2007-12-13 |
2010-02-10 |
Univ Kyushu Nat Univ Corp |
Nanoparticulas que contienen farmaco
|
|
MX350711B
(es)
*
|
2008-02-21 |
2017-09-12 |
Rutgers The State Univ Of New Jersey * |
Composicion y metodo para tratar enfermedades oftalmicas.
|
|
RU2014150367A
(ru)
|
2008-08-29 |
2015-06-27 |
Джензим Корпорейшн |
Лекарственные средства с контролируемым высвобождением, содержащие пептиды
|
|
EP2350118B1
(en)
*
|
2008-09-19 |
2016-03-30 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
|
WO2010033239A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of biphalin peptides
|
|
CN101822642B
(zh)
*
|
2009-03-04 |
2012-02-15 |
上海交通大学医学院 |
一种载有抗肿瘤血管生成药物的多肽修饰的隐形纳米粒及其应用
|
|
CN101822641B
(zh)
*
|
2009-03-04 |
2012-04-11 |
上海交通大学医学院 |
一种k237多肽修饰的隐形纳米粒及其应用
|
|
US12203113B2
(en)
|
2009-07-09 |
2025-01-21 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
CA2770149A1
(en)
|
2009-08-05 |
2011-02-10 |
Pieris Ag |
Controlled release formulations of lipocalin muteins
|
|
CA2791278C
(en)
|
2010-02-25 |
2015-11-24 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
|
US10307372B2
(en)
|
2010-09-10 |
2019-06-04 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
WO2012088409A2
(en)
|
2010-12-23 |
2012-06-28 |
Evonik Degussa Corporation |
Apparatus and methods for preparing an emulsion
|
|
US9327037B2
(en)
|
2011-02-08 |
2016-05-03 |
The Johns Hopkins University |
Mucus penetrating gene carriers
|
|
CN102250251A
(zh)
*
|
2011-06-29 |
2011-11-23 |
河北师范大学 |
一种脑啡肽类似物的聚乙二醇化衍生物
|
|
US20150037375A1
(en)
*
|
2011-07-19 |
2015-02-05 |
Trustees Of Boston University Et Al |
Doping agents and polymeric compositions thereof for controlled drug delivery
|
|
SMT202200355T1
(it)
*
|
2011-12-16 |
2022-11-18 |
Modernatx Inc |
Composizioni di mrna modificato
|
|
CA2863632C
(en)
|
2012-01-19 |
2017-07-11 |
The Johns Hopkins University |
Nanoparticle formulations with enhanced mucosal penetration
|
|
US10159743B2
(en)
|
2012-03-16 |
2018-12-25 |
The Johns Hopkins University |
Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
|
|
EP2825206A1
(en)
|
2012-03-16 |
2015-01-21 |
The Johns Hopkins University |
Controlled release formulations for the delivery of hif-1 inhibitors
|
|
MX2014012625A
(es)
|
2012-04-19 |
2015-05-15 |
Opko Biolog Ltd |
Variantes de oxintomodulina de accion prolongada y metodos para su produccion.
|
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
|
EP3808339B1
(en)
|
2012-05-03 |
2025-11-12 |
Alcon Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
|
HK1208162A1
(en)
|
2012-05-03 |
2016-02-26 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
|
US9889208B2
(en)
|
2012-05-04 |
2018-02-13 |
The Johns Hopkins University |
Lipid-based drug carriers for rapid penetration through mucus linings
|
|
PE20210171A1
(es)
|
2012-11-20 |
2021-01-29 |
Opko Biologics Ltd |
Metodo para aumentar el volumen hidrodinamico de polipeptidos mediante la union a peptidos de gonadotrofina de extremo carboxi
|
|
WO2014098190A1
(ja)
*
|
2012-12-21 |
2014-06-26 |
株式会社 先端医療開発 |
組成物及び飲食物
|
|
WO2014124006A1
(en)
|
2013-02-05 |
2014-08-14 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
|
HK1217092A1
(zh)
|
2013-02-15 |
2016-12-23 |
Kala Pharmaceuticals, Inc. |
治疗性化合物及其用途
|
|
ES2831625T3
(es)
|
2013-02-20 |
2021-06-09 |
Kala Pharmaceuticals Inc |
Compuestos terapéuticos y sus usos
|
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
WO2015061503A1
(en)
*
|
2013-10-22 |
2015-04-30 |
Prolynx Llc |
Conjugates of somatostatin and its analogs
|
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
KR20160099084A
(ko)
|
2013-11-01 |
2016-08-19 |
칼라 파마슈티컬스, 인크. |
치료 화합물의 결정질 형태 및 그의 용도
|
|
WO2015127389A1
(en)
|
2014-02-23 |
2015-08-27 |
The Johns Hopkins University |
Hypotonic enema formulations and methods of use
|
|
KR20150140177A
(ko)
*
|
2014-06-05 |
2015-12-15 |
한미약품 주식회사 |
단백질 및 펩타이드의 면역원성을 감소시키는 방법
|
|
US20160151511A1
(en)
*
|
2014-12-02 |
2016-06-02 |
Antriabio, Inc. |
Proteins and protein conjugates with increased hydrophobicity
|
|
US12459982B2
(en)
|
2014-12-10 |
2025-11-04 |
Opko Biologistics Ltd. |
Methods of producing long acting CTP-modified growth hormone polypeptides
|
|
RU2729731C2
(ru)
|
2014-12-15 |
2020-08-11 |
Зе Джонс Хопкинс Юниверсити |
Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
|
|
KR20240126072A
(ko)
|
2015-01-27 |
2024-08-20 |
더 존스 홉킨스 유니버시티 |
점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
|
|
CA3228939A1
(en)
|
2015-06-19 |
2016-12-22 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
ES2908479T3
(es)
|
2015-08-26 |
2022-04-29 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
|
|
EP3340983B1
(en)
|
2015-08-26 |
2023-10-04 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
|
MX2018004296A
(es)
|
2015-10-08 |
2018-08-01 |
Nektar Therapeutics |
Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
|
|
EP3373978A4
(en)
|
2015-11-12 |
2019-06-26 |
Graybug Vision, Inc. |
AGGREGATION OF MICROPARTICLES FOR THERAPY
|
|
EP3431096B1
(en)
*
|
2016-03-16 |
2024-12-18 |
Xie, Yanhui |
Glucocorticoid combined with polyethylene glycol-modified interleukin-2 for treating respiratory disease
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
EP3455218A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
KR20190036520A
(ko)
|
2016-06-27 |
2019-04-04 |
아칠리온 파르마세우티칼스 인코포레이티드 |
의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물
|
|
RU2019102647A
(ru)
|
2016-07-01 |
2020-08-03 |
Г1 Терапьютикс, Инк. |
Антипролиферационные средства на основе пиримидина
|
|
CA3030156A1
(en)
|
2016-07-07 |
2018-01-11 |
Iovance Biotherapeutics, Inc. |
Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
|
|
SG11201900279UA
(en)
|
2016-07-11 |
2019-02-27 |
Opko Biologics Ltd |
Long-acting coagulation factor vii and methods of producing same
|
|
US10392399B2
(en)
|
2016-09-08 |
2019-08-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
US10253036B2
(en)
|
2016-09-08 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
KR20190051010A
(ko)
|
2016-09-08 |
2019-05-14 |
칼라 파마슈티컬스, 인크. |
치료 화합물의 결정형 및 그의 용도
|
|
KR20190066073A
(ko)
|
2016-10-26 |
2019-06-12 |
이오반스 바이오테라퓨틱스, 인크. |
냉동보존된 종양 침윤 림프구의 재자극
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
KR102618948B1
(ko)
|
2016-11-17 |
2023-12-27 |
이오반스 바이오테라퓨틱스, 인크. |
잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
|
|
WO2018129332A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
|
US11357841B2
(en)
|
2017-01-06 |
2022-06-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
MX2019010381A
(es)
|
2017-03-01 |
2020-01-21 |
Achillion Pharmaceuticals Inc |
Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
|
|
WO2018165294A1
(en)
*
|
2017-03-07 |
2018-09-13 |
North Carolina State University |
Insulin-responsive glucagon delivery patch
|
|
CA3056923A1
(en)
|
2017-03-23 |
2018-09-27 |
Graybug Vision, Inc. |
Drugs and compositions for the treatment of ocular disorders
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
US11254913B1
(en)
|
2017-03-29 |
2022-02-22 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2018209155A1
(en)
|
2017-05-10 |
2018-11-15 |
Graybug Vision, Inc. |
Extended release microparticles and suspensions thereof for medical therapy
|
|
EP3622055A1
(en)
|
2017-05-10 |
2020-03-18 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2018226714A1
(en)
|
2017-06-05 |
2018-12-13 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
EP3641762A4
(en)
|
2017-06-20 |
2021-03-10 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
|
|
CR20200251A
(es)
|
2017-11-17 |
2020-07-17 |
Iovance Biotherapeutics Inc |
Expansión de til de aspirados con aguja fina y biopsias por punción
|
|
CA3083118A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
WO2019118873A2
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US12104172B2
(en)
|
2018-01-08 |
2024-10-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific t-cells
|
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
|
JP2021519337A
(ja)
|
2018-03-26 |
2021-08-10 |
シー4 セラピューティクス, インコーポレイテッド |
Ikarosの分解のためのセレブロン結合剤
|
|
MX2020009857A
(es)
|
2018-03-28 |
2021-01-08 |
Ascendis Pharma Oncology Div A/S |
Conjugados de interleucina-2 (il-2).
|
|
AU2018415814B2
(en)
|
2018-03-29 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
KR20210005138A
(ko)
|
2018-04-27 |
2021-01-13 |
이오반스 바이오테라퓨틱스, 인크. |
종양 침윤 림프구의 확장 및 유전자 편집을 위한 폐쇄 방법 및 면역요법에서의 그의 용도
|
|
US12473532B2
(en)
|
2018-05-10 |
2025-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
JP7538113B2
(ja)
|
2018-08-20 |
2024-08-21 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
補体d因子の医学的障害の治療のための医薬化合物
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
|
US11814391B2
(en)
|
2018-09-06 |
2023-11-14 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for the treatment of medical disorders
|
|
KR20210064269A
(ko)
|
2018-09-20 |
2021-06-02 |
이오반스 바이오테라퓨틱스, 인크. |
동결보존된 종양 샘플로부터의 til의 확장
|
|
CN113365617B
(zh)
|
2018-10-16 |
2025-12-23 |
乔治亚州立大学研究基金会股份有限公司 |
用于医学疾病治疗的一氧化碳前药
|
|
CN111122851A
(zh)
*
|
2018-10-31 |
2020-05-08 |
博阳生物科技(上海)有限公司 |
一种抗干扰剂的制备方法及由此方法制备的抗干扰剂的应用
|
|
CN112969469A
(zh)
|
2018-11-05 |
2021-06-15 |
艾欧凡斯生物治疗公司 |
抗pd-1抗体难治性nsclc患者的治疗
|
|
EP3877511A1
(en)
|
2018-11-05 |
2021-09-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
KR20210099573A
(ko)
|
2018-11-05 |
2021-08-12 |
이오반스 바이오테라퓨틱스, 인크. |
개선된 종양 반응성 t-세포의 선택
|
|
TW202039830A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
|
|
US20220193131A1
(en)
|
2018-12-19 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
|
|
JP7664167B2
(ja)
|
2019-03-01 |
2025-04-17 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用
|
|
WO2020194034A1
(en)
|
2019-03-27 |
2020-10-01 |
Universidad De Chile |
Nanoparticle of chitosan and cyclodextrin containing encapsulated interferon and pharmaceutical compositions that contain it
|
|
WO2020210805A1
(en)
|
2019-04-11 |
2020-10-15 |
The Johns Hopkins University |
Nanoparticles for drug delivery to brain
|
|
EA202192738A1
(ru)
|
2019-04-12 |
2022-03-17 |
С4 Терапьютикс, Инк. |
Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US20220389381A1
(en)
|
2019-10-25 |
2022-12-08 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
EP4073236A1
(en)
|
2019-12-11 |
2022-10-19 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
|
CN115244173A
(zh)
|
2019-12-20 |
2022-10-25 |
英研生物(英国)有限公司 |
用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
|
|
US20250197403A1
(en)
|
2020-02-20 |
2025-06-19 |
Achillion Pharmaceuticals, Inc. |
Heteroaryl compounds for treatment of complement factor d mediated disorders
|
|
CA3165309A1
(en)
|
2020-03-05 |
2021-09-10 |
Christopher G. Nasveschuk |
Compounds for targeted degradation of brd9
|
|
BR112022021020A2
(pt)
|
2020-04-22 |
2023-02-14 |
Iovance Biotherapeutics Inc |
Método de fabricação de um produto de terapia celular, métodos de tratamento do paciente com o produto de terapia celular de expansão e fabricado, e, método de fabricação de um produto de terapia celular
|
|
CA3177413A1
(en)
|
2020-05-04 |
2021-11-11 |
Michelle SIMPSON-ABELSON |
Selection of improved tumor reactive t-cells
|
|
JP2023523855A
(ja)
|
2020-05-04 |
2023-06-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
|
|
KR20230012547A
(ko)
|
2020-05-19 |
2023-01-26 |
쥐원 쎄라퓨틱스, 인크. |
의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
|
|
JP2023527919A
(ja)
|
2020-06-03 |
2023-06-30 |
アセンディス ファーマ オンコロジー ディヴィジョン エー/エス |
Il-2配列及びその使用
|
|
WO2022066774A1
(en)
|
2020-09-23 |
2022-03-31 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement mediated disorders
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
CA3195019A1
(en)
|
2020-10-06 |
2022-04-14 |
Maria Fardis |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022125941A1
(en)
|
2020-12-11 |
2022-06-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
AU2021401302A1
(en)
|
2020-12-17 |
2023-07-06 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
US20240269280A1
(en)
|
2020-12-18 |
2024-08-15 |
Instil Bio (Uk) Limited |
Processing of tumor infiltrating lymphocytes
|
|
WO2022130016A1
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
JP2023554425A
(ja)
|
2020-12-18 |
2023-12-27 |
インスティル バイオ (ユーケイ) リミテッド |
腫瘍浸潤リンパ球の処理
|
|
TW202242085A
(zh)
|
2020-12-31 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
供自動生產腫瘤浸潤淋巴球的裝置和方法
|
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
|
WO2022170219A1
(en)
|
2021-02-05 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Adjuvant therapy for cancer
|
|
WO2022187741A2
(en)
|
2021-03-05 |
2022-09-09 |
Iovance Biotherapeutics, Inc. |
Tumor storage and cell culture compositions
|
|
JP2024510505A
(ja)
|
2021-03-19 |
2024-03-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Cd39/cd69選択に関連した腫瘍浸潤リンパ球(til)拡張及びtilにおける遺伝子ノックアウトのための方法
|
|
US20250345364A1
(en)
|
2021-03-23 |
2025-11-13 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CA3213163A1
(en)
|
2021-03-25 |
2022-09-29 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
|
EP4326287A2
(en)
|
2021-04-19 |
2024-02-28 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
US20240269180A1
(en)
|
2021-05-17 |
2024-08-15 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
EP4373270A2
(en)
|
2021-07-22 |
2024-05-29 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者
|
|
KR20240109615A
(ko)
|
2021-09-09 |
2024-07-11 |
이오반스 바이오테라퓨틱스, 인크. |
Pd-1 talen 녹다운을 사용한 til 생성물의 생성 방법
|
|
WO2023049862A1
(en)
|
2021-09-24 |
2023-03-30 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
EP4423755A2
(en)
|
2021-10-27 |
2024-09-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
JP2024544867A
(ja)
|
2021-11-10 |
2024-12-05 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Cd8腫瘍浸潤リンパ球を利用する拡張治療の方法
|
|
US20250099588A1
(en)
|
2022-01-28 |
2025-03-27 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
JP2025503987A
(ja)
|
2022-01-28 |
2025-02-06 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
ペイロードを発現するように操作された腫瘍浸潤リンパ球
|
|
US20250145950A1
(en)
|
2022-02-01 |
2025-05-08 |
Alaunos Therapeutics, Inc. |
Methods for Activation and Expansion of T Cells
|
|
EP4504220A1
(en)
|
2022-04-06 |
2025-02-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
CA3248034A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
|
EP4565683A1
(en)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
CA3267168A1
(en)
|
2022-09-09 |
2024-03-14 |
Laurent Poirot |
PROCESSES FOR GENERING TIL PRODUCTS USING DOUBLE INACTIVATION OF TALEN PD-1/TIGIT
|
|
WO2024055018A1
(en)
|
2022-09-09 |
2024-03-14 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
EP4612277A1
(en)
|
2022-11-04 |
2025-09-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
|
JP2025539816A
(ja)
|
2022-11-21 |
2025-12-09 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の増幅のための2次元プロセス及びそれからの治療法
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2025015318A2
(en)
|
2023-07-13 |
2025-01-16 |
Iovance Biotherapeutics, Inc. |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
|
WO2025019790A1
(en)
|
2023-07-19 |
2025-01-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
|
|
WO2025054540A1
(en)
|
2023-09-08 |
2025-03-13 |
Iovance Biotherapeutics, Inc. |
Methods of gene-editing using programmable nucleases
|
|
WO2025080865A1
(en)
|
2023-10-11 |
2025-04-17 |
Turnstone Biologics Corp. |
Combination of tumor infiltrating lymphocytes (til) and low dose radiation
|
|
WO2025096638A2
(en)
|
2023-10-30 |
2025-05-08 |
Turnstone Biologics Corp. |
Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|